Description
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Location: CPMC (San Francisco)
Please contact: clinicalresearch@sutterhealth.org for more information about study CheckMate 914
View study details on ClinicalTrials.govPrincipal Investigator
Recruitment Status
Active, Recruiting
Start Date
October 19, 2018